38 results about "Schwann cell" patented technology

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the enteric nervous system, tools for high throughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine.

The application discloses application of skin precursor cell induced Schwann cell derived vesicles (SKP-SC-EVs) in preparation of a product for treating Parkinson's disease, wherein the SKP-SC-EVs have a protective effect in rotenone or MPP+-induced cell injury, and in a MPTP-induced mouse Parkinson's disease model, the SKP-SC-EVs can be given by a nasal instillation method to improve the motor ability of the mouse and restore the olfactory function, and the product can be used for research and treatment of Parkinson's disease.

The invention discloses siRNA capable of knocking down Pr18a9 gene expression and application of the siRNA, and relates to the technical field of biological medicine. The invention provides a positive-sense strand sequence and an antisense strand sequence of the siRNA, and the siRNA is used for preparing a preparation for promoting Schwann cell survival. According to the invention, the Prl8a9 gene of SCs is knocked down by virtue of a small interfering RNA technology; by improving the proliferation and migration capabilities of the Schwann cells, the apoptosis rate of the Schwann cells is reduced, and the survival rate of the Schwann cells is further improved. Meanwhile, a transcriptome sequencing technology is applied, key genes and pathways of Schwann cells treated by siPr18a9 are deeply excavated, and a theoretical support is provided for research on a repair mechanism after peripheral nerve injury.

The present invention relates to a pharmaceutical composition and cell therapy agent for the prevention or treatment of neurological diseases, comprising Schwann cell precursors (SCPs) or Schwann cells differentiated therefrom, derived from pluripotent stem cells (PSCs) or somatic cells, and natural killer (NK) cells as active ingredients. Specifically, the Schwann cell precursors (SCPs) express at least one selected from the group consisting of GAP43, SOX10, IGFBP2, and combinations thereof; the Schwann cells (SCs) express at least one selected from the group consisting of S100B, SOX10, and combinations thereof; and the natural killer (NK) cells express CD56 + CD16 + It is characterized by expressing at least one selected from the group consisting of the and combinations thereof.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

The invention provides a composite active dressing for neural restoration and a preparation method and application thereof, and relates to the technical field of medical materials. The composite active dressing comprises a transdermal inner layer and a small extracellular vesicle slow-release outer layer, the transdermal inner layer is of a membrane-shaped structure and comprises a composite active component and a hydrogel matrix material, and the composite active component is selected from one or more of an anti-inflammatory component, a microcirculation improving component, an antioxidant component and a neurotrophic component; the small extracellular vesicle sustained-release outer layer is of a three-dimensional network structure and comprises small extracellular vesicles and a hydrogel matrix material. According to the invention, stable loading and layered deep delivery and release of the small extracellular vesicles are realized, the inflammatory response and microcirculation state of an injured part are improved, proliferation migration and remyelination of Schwann cells can be promoted, and axon regeneration and effective repair of nerve injury can also be promoted.

The application belongs to the technical field of nerve grafts, and discloses a multilayer composite capacitive film, a preparation method and application of the multilayer composite capacitive film in nerve repair scaffolds. The scaffold is composed of three layers, namely, an A layer, a B layer and an A layer. The A layer is a sandwiched layer on both sides, and comprises a mixture of chitosan (or silk fibroin or a decellularized matrix) and a conductive polymer PEDOT:PSS and a crosslinking agent polyethylene glycol diglycidyl ether (PEGDE). The B layer is a middle hydrogel sandwiched layer, and comprises methacrylated gelatin (Gel-MA). The A layers on both sides are bonded through the B layer to form a viscoelastic hydrogel after ultraviolet light irradiation, and the composite capacitive scaffold in a multilayer structure with a through middle cavity is obtained after curing and air drying. The formed scaffold has good electrical conductivity, mechanical properties and biological safety, and can effectively induce the proliferation, migration and differentiation of RSC96 Schwann cells and nerve system cells PC12, thereby providing a good physical stable support and a favorable microenvironment for peripheral nerve injury repair.

The present invention provides viral vectors for use in the treatment and prevention of diseases associated with Schwann cells by delivering polynucleotides specifically to Schwann cells and achieving Schwann cell specific expression. The present invention has particular application in treatment and prevention of Charcot-Marie-Tooth disease and other demyelinating neuropathies. The preferred vectors are adeno-associated vectors (AAV) having a Schwann cell-specific promoter from the Myelin Protein Zero (Mpz, P0) or a minimal Mpz promoter.

The invention relates to a method for evaluating ferroptosis sensitivity of NF2-related vestibular nerve sheath tumor Schwann cells. The method comprises the following steps: constructing NF2-mutated immortalized Schwann cells; carrying out ferroptosis induction and intervention experiments, and establishing a plurality of experiment groups; detecting ROS level, Fe < 2 + > concentration, GSH content, MDA level and protein expression of GPX4 and the like of each group of cells; sample preparation is carried out through a TEM method, and mitochondrial volume and morphological characteristics of each group of cells in a ferroptosis state are observed; detecting the cell viability, cell membrane damage and apoptosis proportion of each group of cells; and evaluating the influence of NF2 deletion on ferroptosis sensitivity. According to the method, a ferroptosis cell modeling scheme in which Erastin (an inducer) and Fer-1 (an inhibitor) are jointly intervened is designed, and a multi-dimensional ferroptosis evaluation system is combined, so that the stability and the result reproducibility of NF2 related vestibular nerve sheath tumor Schwann cell ferroptosis state evaluation are remarkably improved.

The invention discloses a method for inducing and differentiating Schwann cells by using olfactory ensheathing cells and mesenchymal stem cells. The method comprises the following steps: mixing adipose-derived mesenchymal stem cells and olfactory ensheathing cells for culturing, and inducing to obtain the Schwann cells. According to the method, the adipose-derived stem cells are differentiated into the Schwann cells through induction culture, the differentiation speed is high, and the functional Schwann cells with the remarkably increased number can be obtained.

The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells into Schwann cell precursors and Schwann cells, and Schwann cell precursors and Schwann cells generated by such methods. The presently disclosed subject matter also provides for uses of such Schwann cell precursors and Schwann cells for regeneration of PNS and / or CNS, for prevention and / or repair of myelin damages, and / or for prevention and / or treatment of Schwann cell related disorders (e.g., peripheral neuropathy, e.g., Diabetic Peripheral Neuropathy).

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA as a marker in detection of hand-foot-mouth disease complicated with nerve injury. The application first discovers that hsa_circ_0069335 as a marker is applied in prediction of hand-foot-mouth disease complicated with nerve injury. In an external verification queue, there is no marker in serum samples of patients with nerve injury symptoms, and the area under the ROC curve is 1, which indicates that the marker can be used as a marker of hand-foot-mouth disease complicated with nerve injury, and has excellent specificity and sensitivity. Further, the application discovers that EV71 infection inhibits growth of Schwann cells, myelin formation is damaged, and causes significant damage to the nervous system, which is related to the hsa_circ_0069335 / miR-29b-3p / PMP22 pathway. The discovery may provide a key molecular target for early warning and treatment of severe hand-foot-mouth disease, so as to accelerate the development progress of therapeutic drugs.

The invention discloses application of an ETS family transcription factor ELK1 in preparation of a medicine for treating peripheral neuropathy. The invention proposes and verifies that the ETS family transcription factor ELK1 can effectively regulate and control the physiological activity of Schwann cells in a peripheral nervous system for the first time, especially the directed migration function and migration speed; a new direction is provided for research and development of drugs for treating Schwann cell-derived diseases and diseases caused by nerve injury.

This invention discloses a self-generating microneedle nerve conduit that releases NGF in response to ultrasound and its preparation method, comprising: preparing a mixed solution containing a substrate material, a piezoelectric material, and a conductive material; pouring the mixed solution into a microneedle array mold, vacuum drying, and then annealing; removing the treated microneedle patch; immersing the microneedle patch in a mixed solution containing growth factors for half an hour, then removing it and drying it overnight at room temperature; immersing the growth factor-loaded microneedle patch in a coating solution and quickly removing it and placing it in a low-temperature environment overnight; drying the obtained microneedle patch and rolling it into a tubular shape to obtain the desired nerve conduit. The microneedle array structure on the surface of the nerve conduit of this invention can achieve efficient piezoelectricity through the tip effect principle, and can simultaneously achieve electrically controlled release of growth factors, promoting cell proliferation and differentiation, and accelerating the formation of Schwann cell Bunner bands.

The invention discloses an extracellular vesicle for treating facial nerve injury and a preparation method thereof. The hNSCs-EVs are separated from an hNSCs conditioned culture medium through an ultracentrifugation method, the particle size of the hNSCs-EVs is 100-150nm, and the hNSCs-EVs express CD9, CD63 and TSG101 markers. Experiments prove that when hNSC-EVs is locally injected to the injured part of facial nerves, functional recovery of the facial nerves can be remarkably promoted, electrophysiological signals can be improved, and axon regeneration, myelin sheath formation and Schwann cell activation can be effectively promoted. The invention provides a brand new treatment strategy which is safe, effective, easy to store and standard for facial nerve injury, and has a wide clinical application prospect.

The invention relates to a sericin-akermanite composite nerve conduit. A preparation method of the sericin-akermanite composite nerve conduit comprises the following steps: dissolving silkworm cocoons with a lithium bromide solution to obtain a sericin solution; the sericin solution and the Tris-Hcl aqueous solution are mixed and added into a dialysis bag; adding the dialysis bag into the dialysate for dialysis; centrifuging, filtering and collecting the dialyzed sericin solution; adding the sericin solution into a polyethylene glycol supersaturated solution, and concentrating; adding akermanite into the genipin solution to prepare a cross-linking solution; mixing the sericin solution and the cross-linking solution, upside down and uniformly mixing, and injecting into a mold; and incubating to obtain the sericin hydrogel. And freezing the sericin hydrogel, demolding and freeze-drying to obtain the sericin-akermanite composite nerve conduit. According to the present invention, the cell compatibility, the degradability and the immunogenicity are good; proliferation and migration of nerve regeneration key cells-Schwann cells and secretion of various nutritional factors can be promoted; and the structural regeneration and functional recovery of long-distance peripheral nerve dissection are promoted.

The invention provides walnut-derived extracellular membrane vesicles and application thereof in peripheral nerve injury repair, and relates to the technical field of biological medicines. The walnut-derived extracellular membrane vesicles (WEVs) prepared by the invention show typical vesicle form and nano-scale particle size distribution, and can still keep structural integrity after freeze-drying and long-term storage, thereby supporting the feasibility of standardized preparation and preservation of the walnut-derived extracellular membrane vesicles (WEVs). In the functional level, the WEVs can be efficiently internalized by Schwann cells (SCs) through an energy-dependent process, and the process accords with gridding protein mediated endocytosis characteristics; meanwhile, the WEVs show good biocompatibility and biological safety in vitro and in vivo. In addition, the WEVs can promote remyelination of PNI model rats, improve motion and sensory functions of the PNI model rats and relieve muscular atrophy conditions of the PNI model rats, and has an obvious treatment effect on the PNI model rats. The WEVs are expected to be used as a plant-derived nano candidate drug for treating peripheral nerve injury.

The invention discloses a guided dental pulp stem cell extracellular matrix nerve scaffold and a preparation method thereof, and belongs to the technical field of biological materials. The method comprises the following steps: culturing dental pulp stem cells, stimulating the dental pulp stem cells to secrete an extracellular matrix, and carrying out decellularization treatment to obtain DPSC-dECM; the preparation method comprises the following steps: preparing the DPSC-ECM into a suspension, mixing the suspension with a PLCL solution, spinning by adopting an electrostatic spinning technology to form an oriented DPSC-ECM membrane, rolling to form a catheter inner layer, spinning a PLCL fiber layer on an outer layer, and drying to obtain the double-layer tubular nerve stent. The inner layer of the stent is composed of DPSC-ECM / PLCL composite oriented nanofibers, and can provide active biological signals and oriented physical guidance at the same time, effectively maintain Schwann cell repair phenotypes, significantly enhance cell adhesion, proliferation, oriented migration, autophagy and secretion functions, and promote angiogenesis at the same time, thereby achieving good axon regeneration; the outer layer PLCL fiber provides mechanical support; the problems that a traditional nerve repair material is difficult to maintain the Schwann cell repair function and is insufficient in guidance are solved, and a new strategy is provided for peripheral nerve defect repair.

The present invention relates to a pharmaceutical composition and a cell therapy agent for preventing or treating a neurological disease, comprising Schwann cell precursors (SCPs) prepared from pluripotent stem cells (PSCs) or somatic cells, or Schwann cells (SCs) differentiated therefrom; and natural killer (NK) cells as active ingredients. Specifically, the present invention is characterized in that the SCPs express one or more selected from the group consisting of GAP43, SOX10, IGFBP2, and a combination thereof; the SCs express one or more selected from the group consisting of S100B, SOX10, and a combination thereof; and the NK cells express one or more selected from the group consisting of CD56+, CD16+, and a combination thereof.

The present disclosure provides: a new method for producing clinically usable Schwann precursor cells; and a new method for producing Schwann cells. The present disclosure provides a method for producing Schwann precursor cells, the method comprising: culturing human pluripotent stem cells on a substrate in which a culture region is spatially limited, to obtain a cell cluster of human pluripotent stem cells having a controlled size; culturing the cell cluster and differentiating the same into a neural rosette; and obtaining Schwann precursor cells from the neural rosette.

The application discloses a kind of recombinant type I humanized collagen and its preparation method and application, belong to genetic engineering field, by bioinformatics method to the core function fragment of human type I collagen alpha 1 chain as shown in SEQ ID NO.1 is analyzed, design and construct the length of 330 amino acids of recombinant type I humanized collagen rCol1, sequence as shown in SEQ ID NO.3;Recombinant type I humanized collagen rCol1 is hydrophilic protein, with good biocompatibility, and with lower antigenicity, can efficiently promote Schwann cell and neuron neurite regeneration;The recombinant type I humanized collagen rCol1 prepared by the method has high purity, no virus hidden danger, has obvious expression abundance;This protein has important application in biomedical, regenerative medicine, tissue engineering, beauty care and cosmetic preparation and the like.

The invention provides a preparation method of a nerve conduit, and belongs to the technical field of biological tissues, and the preparation method comprises the following steps: constructing Fe3O4 (at) PDA magnetic nanoparticles; loading the Fe3O4 (at) PDA magnetic nanoparticles with stem cells to form magnetized stem cells; performing magnetic field stimulation treatment on the magnetized stem cells to induce and differentiate the magnetized stem cells into magnetized Schwann cells; and constructing a nerve conduit loaded with the magnetized Schwann cells, and directionally migrating the magnetized Schwann cells in a magnetic field to induce directional growth of axons. The Schwann cells are terminally differentiated cells and have fewer sources, and exogenous Schwann cells have biological safety risks, so that the magnetized Schwann cells with space-time specific distribution are formed by regulating and controlling the autologous magnetized stem cells to quickly differentiate through a directional low-intensity magnetic field; nutrition and direction guidance are provided for nerve fiber growth by inducing directional migration and secreting neurotrophic factors, and the method has the advantages of being simple, rapid, low in biological safety risk and the like.

The present disclosure relates to polypeptides for targeting, purifying, and / or loading extracellular vesicles (EVs) such as exosomes. The present disclosure also relates to nucleic acids encoding said polypeptides, EVs comprising said polypeptides, methods of making and / or purifying said EVs, and medical uses of said EVs. The present disclosure also relates to EVs for targeting Schwann cells, methods of making and / or purifying said EVs, and medical uses of said EVs

Provided herein are methods of treating a subject having a peripheral nervous system (PNS) myelination condition, comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a polypeptide having cholesterol efflux activity, wherein the polypeptide is selected from CS6253 and variants thereof. The PNS myelination condition can be a condition characterized by PMP22 dysfunction in the PNS, a PNS myelination disorder resulting from abnormal ABCA1 regulated cholesterol transport disorder, a demyelinating condition resulting from Schwann cell dysfunction and a non-hereditary PNS myelination condition.

The invention belongs to the technical field of biological medicines, and particularly relates to application of miR-29b-3p in preparation of a product for predicting and treating EV71 virus infection. The application of the miR-29b-3p as the marker in predicting and treating the hand-foot-and-mouth disease complicated with the nerve injury is found for the first time. In an external verification queue, the existence of the marker cannot be completely detected in a serum sample of a patient with a nerve injury symptom, and the area under an ROC curve of the marker is 1, so that the marker can be used as the marker of the hand-foot-and-mouth disease complicated with the nerve injury and has excellent specificity and sensitivity. Further, EV71 infection inhibits growth of Schwann cells, myelin sheath formation is damaged, and the nervous system is remarkably damaged. After miR-29b-3p is exogenously supplemented in a mouse model, the expression of EV71 virus in mouse brain tissues can be remarkably reduced, the nerve defect state score of EV71 infected mice is reduced, and the inflammatory state of the EV71 infected mice is relieved.

The invention relates to the field of biological medicine, and provides a pharmaceutical composition for repairing peripheral nerve injury and application of the pharmaceutical composition. The pharmaceutical composition comprises a growth arrest specific protein 6 and a caspase-1 inhibitor, and the growth arrest specific protein 6 and the caspase-1 inhibitor can be jointly administered to promote functional recovery after peripheral nerve injury. The combined strategy can inhibit adverse effects on Tyro3 (TAM receptor family member) caused by activation of inflammasome-related caspase-1, and enhance Gas6-Tyro3-related downstream survival promotion and myelination promotion signal pathways at the same time, so that the myelination regeneration and wrapping capability of Schwann cells on damaged axons can be improved, and regeneration and repair of peripheral nerves can be promoted. The pharmaceutical composition can be prepared into an injection, a solution, a gel or a sustained release preparation. The medicine kit can be packaged separately and matched with a specification to realize combined administration.

The invention discloses an application of a non-traditional myosin IF gene MYO1F in preparation of a peripheral nerve growth regulation and control medicine. The invention proposes and verifies that the expression of the non-traditional myosin IF gene MYO1F can effectively regulate and control the physiological activity of neurons of a peripheral nervous system for the first time, for example, the expression of the MYO1F is inhibited to effectively inhibit the proliferation and migration of Schwann cells; the invention provides a new direction for research and development of drugs for treating Schwann cell-derived diseases and diseases caused by nerve injury.

Provided herein are, in various embodiments, methods and compositions for differentiating olfactory mucosa-derived mesenchymal stem cells (OM-MSC). In certain embodiments, the disclosure provides for media to differentiate OM-MSCs. In still further embodiments, the disclosure provides for methods and compositions using differentiated OM-MSCs for the treatment of nerve repair. In particular embodiments, the disclosure provides for novel treatments of peripheral nerve repair.